Frontlight ResearchEarly access
Acute myeloid leukaemia trials in United States
334 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleAssessment of Geriatric Evaluations Impact on New AML Guidance
- Where
- Philadelphia
- Age
- 50 years and over
- People
- 100
- Run by
- Abramson Cancer Center at Penn Medicine
See details and how to joinNCT05909501 - Phase 2Not yet taking people in United StatesAutomated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
- Where
- Palo Alto
- Age
- 18 years to 70 years
- People
- 30
- Run by
- Stanford University
See details and how to joinNCT07634536 - Phase 1Taking peopleA Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Where
- Atlanta, Columbus, Duarte, Hackensack, Houston, Kansas City, Milwaukee, New York, Sacramento, Seattle, Stanford, Tampa
- Age
- 12 years to 78 years
- People
- 300
- Run by
- Orca Biosystems, Inc.
See details and how to joinNCT03802695 - Phase 1Taking peopleA Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Duarte
- Age
- 18 years and over
- People
- 12
- Run by
- City of Hope Medical Center
See details and how to joinNCT06763341 - Phase 2Taking peopleLiposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- Where
- Houston
- Age
- 18 years and over
- People
- 72
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT03629171 - Phase 1Taking peopleA Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
- Where
- Houston
- Age
- 18 years and over
- People
- 30
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06401603 - Phase 1/2Taking peopleA Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- Where
- Houston
- Age
- 18 years and over
- People
- 40
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06548230 - Phase 1Taking peopleRuxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Columbus, Dallas, Portland
- Age
- 18 years and over
- People
- 51
- Run by
- Jennifer Saultz
See details and how to joinNCT03874052 - Phase 1/2Taking peopleA Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
- Where
- Houston
- Age
- 12 years and over
- People
- 43
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT05360160 - Phase 2Taking peopleMetronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
- Where
- Richmond
- Age
- 18 years and over
- People
- 40
- Run by
- Virginia Commonwealth University
See details and how to joinNCT07710534 - Phase 1Taking peopleEdetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- Where
- Houston
- Age
- 1 year and over
- People
- 58
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT03630991 - Phase 1/2Taking peopleA Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Where
- Baltimore, Boston, Houston, New York
- Age
- 12 years and over
- People
- 8
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06284486 - Phase 1Taking peopleDose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
- Where
- Houston
- Age
- 18 years and over
- People
- 44
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06769490 - Phase 2Taking peopleDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Where
- Seattle
- Age
- 18 years and over
- People
- 25
- Run by
- University of Washington
See details and how to joinNCT04282187 - Phase 3Taking peopleA Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Where
- Akron, Albany, Albuquerque, Allentown, Ann Arbor, Asheville, Atlanta, Augusta, Aurora, Austin, Baltimore, Bangor, Bethesda, Birmingham, Boise, Boston, Brooklyn, Buffalo, Burlington, Chapel Hill, Charleston, Charlotte, Charlottesville, Chattanooga, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Corpus Christi, Dallas, Danville, Dayton, Denver, Des Moines, Detroit, Downey, Duarte, Durham, East Lansing, El Paso, Falls Church, Fargo, Fort Lauderdale, Fort Myers, Fort Worth, Gainesville, Grand Rapids, Green Bay, Greenville, Hackensack, Hartford, Hershey, Hollywood, Honolulu, Houston, Indianapolis, Iowa City, Jackson, Jacksonville, Kalamazoo, Kansas City, Knoxville, Las Vegas, Lebanon, Lexington, Little Rock, Loma Linda, Long Beach, Los Angeles, Louisville, Loxahatchee Groves, Madera, Madison, Marshfield, Maywood, Mesa, Miami, Milwaukee, Mineola, Minneapolis, Mobile, Morristown, Nashville, Neptune City, Newark, New Brunswick, New Haven, New Hyde Park, New Orleans, New York, Norfolk, Oakland, Oak Lawn, Oklahoma City, Omaha, Orange, Orlando, Palo Alto, Park Ridge, Paterson, Pensacola, Peoria, Philadelphia, Phoenix, Pittsburgh, Portland, Portsmouth, Providence, Reno, Richmond, Roanoke, Rochester, Royal Oak, Sacramento, Salt Lake City, San Antonio, San Diego, San Francisco, Santa Barbara, Savannah, Scarborough, Seattle, Sioux Falls, Spokane, Springfield, St Louis, Stony Brook, St. Petersburg, Syracuse, Tacoma, Tampa, Temple, The Bronx, Toledo, Tucson, Valhalla, Washington D.C., West Palm Beach, Wilmington, Winston-Salem, Worcester
- Age
- 6 months to 21 years
- People
- 1,400 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT04293562 - Phase 1Taking peopleCLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Where
- Seattle
- Age
- 18 years and over
- People
- 120
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT04375631 - Phase 2Taking peopleA Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- Where
- Boston, Charlotte, Chicago, Cincinnati, Fort Worth, Madera, Memphis, Orange, San Diego, Washington D.C.
- Age
- 29 days to 21 years
- People
- 70
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT05955261 - Phase 1Taking peopleClinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
- Where
- Houston
- Age
- 12 years and over
- People
- 18
- Run by
- Hemogenyx Pharmaceuticals LLC
See details and how to joinNCT06786533 - Phase 2Taking peopleVenetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- Where
- Miami, Portland
- Age
- 18 years and over
- People
- 40
- Run by
- OHSU Knight Cancer Institute
See details and how to joinNCT06504459 - Phase 2Taking peopleEvaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Where
- Baltimore, Birmingham, Buffalo, Charlotte, Easton, Greenville, Hackensack, Houston, Los Angeles, New York, Salt Lake City, Valhalla, Westbury, Worcester
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06824168 - Phase 2Taking people(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Atlanta, Birmingham, Boston, Charleston, Chicago, Cleveland, Duarte, Hialeah, Houston, Los Angeles, New York, Phoenix, Salt Lake City, Stanford
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 1Taking peopleA Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
- Where
- Memphis
- Age
- Up to 25 years
- People
- 29
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT06810583 - Phase 2Taking peopleCo-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- Where
- Cleveland
- Age
- 18 years and over
- People
- 36
- Run by
- Case Comprehensive Cancer Center
See details and how to joinNCT06904482 - Phase 1/2Taking peopleIvosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Where
- Boston, Cleveland, Houston, Portland
- Age
- 18 years and over
- People
- 96
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT03471260 - Phase 2Taking peopleEnasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- Where
- Houston
- Age
- 18 years and over
- People
- 50
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT03683433